Your browser doesn't support javascript.
Changes Afoot: 2022 Outlook for Pharma and its People
Pharmaceutical Technology Europe ; 34(1):10-13, 2022.
Article in English | ProQuest Central | ID: covidwho-20243764
ABSTRACT
[...]we've seen more companies diversifying their portfolios and investing in therapies for rare diseases so that advanced therapies, and in particular, gene therapies-which were deemed experimental and risky when I was involved with the European Medicines Agency's Committee for Advanced Therapies some 10-12 years ago-take centre stage," Schneider continues. The year's expectations were unsurprisingly centred around COVID-19 for Martin Lush, global vice president. "Many big pharma companies will continue down the path of externalising services for small molecules and/or known molecules maintenance, to keep their focus on novel molecules," she explains. [...]of this complexity, there can be much negotiation and, hence, delay in access to medicines, he explains.
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Language: English Journal: Pharmaceutical Technology Europe Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Language: English Journal: Pharmaceutical Technology Europe Year: 2022 Document Type: Article